Rdad these results carefully noting use of Pembro with high risk melanoma patients increased length of time to recurrance, but there are concerns about use of Pembro with stage 2 which may eliminate it as a metastatic intervention.
medpagetoday.com/meetingcov...
Peace,
missy
Yes I read about that this week too. Very good news however… so many questions and doubts about the viability of real practice change. Increase of patients with AEs, the challenge of possibly re-challenging with a PD-1 inhibitor in a higher stage setting, not to mention the fact that there would be an increased need for medical oncologists specialized in melanoma to treat all these patients. But I am very happy things are moving so fast in the melanoma research community.
Thank you for posting
Love ❤️
